BetterLife Pharma Inc. (BETRF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -3.24 Million CAD | 65.75% |
| 2023 | -9.46 Million CAD | 7.32% |
| 2022 | -10.2 Million CAD | -28.96% |
| 2021 | -7.91 Million CAD | 57.74% |
| 2020 | -18.73 Million CAD | -173.68% |
| 2019 | -6.84 Million CAD | -428.71% |
| 2018 | -1.29 Million CAD | 83.6% |
| 2017 | -7.89 Million CAD | 34.28% |
| 2016 | -12.01 Million CAD | -9081.83% |
| 2015 | -130.81 Thousand CAD | -70.13% |
| 2014 | -76.88 Thousand CAD | 13.51% |
| 2013 | -88.89 Thousand CAD | 75.48% |
| 2012 | -362.51 Thousand CAD | -151.16% |
| 2011 | -144.33 Thousand CAD | -21.33% |
| 2010 | -118.96 Thousand CAD | 81.79% |
| 2009 | -653.23 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -3.2 Million CAD | 66.07% |
| 2024 Q3 | -856.47 Thousand CAD | 7.61% |
| 2024 Q1 | -836.9 Thousand CAD | -32.71% |
| 2024 Q4 | -730.25 Thousand CAD | 14.74% |
| 2024 Q2 | -926.97 Thousand CAD | -10.76% |
| 2023 Q2 | -1.23 Million CAD | 59.66% |
| 2023 Q1 | -3.05 Million CAD | -35.37% |
| 2023 Q4 | -630.62 Thousand CAD | 86.12% |
| 2023 Q3 | -4.54 Million CAD | -268.98% |
| 2023 FY | -9.46 Million CAD | 7.32% |
| 2022 Q3 | -2.14 Million CAD | 36.16% |
| 2022 FY | -10.2 Million CAD | -28.96% |
| 2022 Q2 | -3.35 Million CAD | -36.65% |
| 2022 Q1 | -2.45 Million CAD | -10.29% |
| 2022 Q4 | -2.25 Million CAD | -5.3% |
| 2021 Q3 | -2.88 Million CAD | -84.52% |
| 2021 FY | -7.91 Million CAD | 57.74% |
| 2021 Q1 | -1.1 Million CAD | 89.47% |
| 2021 Q2 | -1.56 Million CAD | -41.73% |
| 2021 Q4 | -2.22 Million CAD | 22.82% |
| 2020 Q3 | -2.33 Million CAD | 45.11% |
| 2020 Q2 | -4.25 Million CAD | -155.98% |
| 2020 Q1 | -1.66 Million CAD | -7.54% |
| 2020 FY | -18.73 Million CAD | -173.68% |
| 2020 Q4 | -10.47 Million CAD | -348.71% |
| 2019 Q4 | -1.54 Million CAD | 16.61% |
| 2019 Q2 | -1.53 Million CAD | 17.17% |
| 2019 Q3 | -1.85 Million CAD | -20.37% |
| 2019 Q1 | -1.85 Million CAD | -399.22% |
| 2019 FY | -6.84 Million CAD | -428.71% |
| 2018 Q2 | -310.03 Thousand CAD | 20.42% |
| 2018 FY | -1.29 Million CAD | 83.6% |
| 2018 Q4 | -372.16 Thousand CAD | -57.1% |
| 2018 Q3 | -236.89 Thousand CAD | 23.59% |
| 2018 Q1 | -389.6 Thousand CAD | 57.44% |
| 2017 FY | -7.89 Million CAD | 34.28% |
| 2017 Q1 | -4.18 Million CAD | 45.03% |
| 2017 Q4 | -915.49 Thousand CAD | 1.14% |
| 2017 Q2 | -1.54 Million CAD | 63.17% |
| 2017 Q3 | -926.08 Thousand CAD | 39.89% |
| 2016 Q4 | -7.6 Million CAD | -73636.19% |
| 2016 FY | -12.01 Million CAD | -9081.83% |
| 2016 Q1 | -1.44 Million CAD | -2121.37% |
| 2016 Q2 | -2.94 Million CAD | -103.53% |
| 2016 Q3 | -10.32 Thousand CAD | 99.65% |
| 2015 Q3 | -27.52 Thousand CAD | 8.17% |
| 2015 FY | -130.81 Thousand CAD | -70.13% |
| 2015 Q1 | -8194.00 CAD | 61.25% |
| 2015 Q2 | -29.97 Thousand CAD | -265.77% |
| 2015 Q4 | -65.12 Thousand CAD | -136.61% |
| 2014 Q2 | -32.51 Thousand CAD | -139.93% |
| 2014 Q4 | -21.14 Thousand CAD | -23.89% |
| 2014 Q3 | -17.06 Thousand CAD | 47.5% |
| 2014 Q1 | -13.55 Thousand CAD | -412.93% |
| 2014 FY | -76.88 Thousand CAD | 13.51% |
| 2013 Q2 | -33.11 Thousand CAD | 6.79% |
| 2013 FY | -88.89 Thousand CAD | 75.48% |
| 2013 Q1 | -35.52 Thousand CAD | -192.03% |
| 2013 Q3 | -24.58 Thousand CAD | 25.77% |
| 2013 Q4 | 4330.00 CAD | 117.61% |
| 2012 Q3 | -154.36 Thousand CAD | -110.45% |
| 2012 Q2 | -73.35 Thousand CAD | 58.69% |
| 2012 FY | -362.51 Thousand CAD | -151.16% |
| 2012 Q4 | 38.6 Thousand CAD | 125.01% |
| 2012 Q1 | -177.57 Thousand CAD | -238.45% |
| 2011 Q2 | -42.52 Thousand CAD | -57.19% |
| 2011 Q4 | -52.46 Thousand CAD | -159.92% |
| 2011 Q3 | -20.18 Thousand CAD | 52.53% |
| 2011 FY | -144.33 Thousand CAD | -21.33% |
| 2011 Q1 | -27.05 Thousand CAD | -68.16% |
| 2010 Q4 | -16.08 Thousand CAD | -13.96% |
| 2010 Q2 | -75.96 Thousand CAD | -493.3% |
| 2010 FY | -118.96 Thousand CAD | 81.79% |
| 2010 Q3 | -14.11 Thousand CAD | 81.42% |
| 2010 Q1 | -12.8 Thousand CAD | 0.0% |
| 2009 FY | -653.23 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 95.486% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 165.928% |
| SQZ Biotechnologies Company | -75.82 Million USD | 95.727% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 81.844% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.959% |
| Mesoblast Limited | -84.14 Million USD | 96.149% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -110.946% |
| Genus plc | 6.4 Million USD | 150.629% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 133.259% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -247.897% |
| Marizyme, Inc. | -34.08 Million USD | 90.494% |
| ContraFect Corporation | -56.88 Million USD | 94.304% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 61.195% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 28.86% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -131.117% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -13.672% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -17.791% |
| MultiCell Technologies, Inc. | -722.81 USD | -448183.92% |
| Accustem Sciences Inc. | -3.74 Million USD | 13.511% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 94.507% |
| EV Biologics, Inc. | -483.06 Thousand USD | -570.771% |
| Q BioMed Inc. | -3.44 Million USD | 5.96% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 191.532% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -731.748% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -23.319% |
| Biomind Labs Inc. | -1 Million USD | -220.942% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 33.595% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 51.26% |
| Skye Bioscience, Inc. | -13.67 Million USD | 76.3% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -63.115% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -10718.112% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 35.767% |
| IMV Inc. | -38.67 Million USD | 91.621% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 79.582% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -67.661% |
| GB Sciences, Inc. | -1.42 Million USD | -128.104% |
| Alpha Cognition Inc. | -9.7 Million USD | 66.615% |
| HST Global, Inc. | -140.9 Thousand USD | -2199.56% |
| CSL Limited | 3.7 Billion USD | 100.088% |
| Halberd Corporation | -75.05 Thousand USD | -4217.443% |
| Enzolytics Inc. | -2.14 Million USD | -50.793% |
| Resverlogix Corp. | -12.74 Million USD | 74.584% |
| Affymax, Inc. | -15.04 Million USD | 78.464% |
| SYBLEU INC | -149.18 Thousand USD | -2072.034% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -2.271% |
| argenx SE | -425.04 Million USD | 99.238% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 94.163% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -210.368% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -105.162% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 4.838% |
| AVAX Technologies, Inc. | 6.69 Million USD | 148.413% |
| Zenith Capital Corp. | -8.94 Million USD | 63.768% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.221% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -18499.627% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -31.968% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1789.248% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 94.106% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -11.684% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -229.275% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -73.798% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -157.981% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -61.628% |
| BioStem Technologies, Inc. | -7.77 Million USD | 58.346% |
| ONE Bio Corp. | 13.68 Million USD | 123.683% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1685.404% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -142.636% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -188.045% |
| Agentix Corp. | -1.37 Million USD | -136.211% |
| LadRx Corporation | -3.82 Million USD | 15.257% |
| Cell Source, Inc. | -4.32 Million USD | 25.087% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -679.881% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -371.685% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -371.685% |
| NovAccess Global Inc. | -2.46 Million USD | -31.356% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -10.988% |
| Itoco Inc. | -919.14 Thousand USD | -252.53% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 23.551% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -189.566% |
| Kadimastem Ltd | -3.04 Million USD | -6.578% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1138.028% |
| CytoDyn Inc. | -18.05 Million USD | 82.056% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -12773.425% |
| Mobile Lads Corp. | -554.55 Thousand USD | -484.301% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1372.315% |
| Qrons Inc. | -643.67 Thousand USD | -403.395% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -473.775% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -45.31% |
| Rebus Holdings, Inc. | -664 Thousand USD | -387.988% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -78.396% |
| International Stem Cell Corporation | -663 Thousand USD | -388.724% |
| Bioxytran, Inc. | -3.82 Million USD | 15.18% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -6055.473% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -15830.388% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 91.065% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -100.262% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -340.349% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -4.154% |
| Neutra Corp. | -229.48 Thousand USD | -1311.956% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 81.526% |
| PureTech Health plc | -146.19 Million USD | 97.784% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 84.923% |
| IXICO plc | -1.43 Million USD | -125.486% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 65.86% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.34% |
| CSL Limited | 3.81 Billion USD | 100.085% |
| Cellectis S.A. | -108.85 Million USD | 97.023% |